Solid Biosciences (SLDB) Operating Leases (2019 - 2026)

Solid Biosciences (SLDB) has 8 years of Operating Leases data on file, last reported at $18.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 10.57% year-over-year to $18.5 million; the trailing twelve-month figure through Mar 2026 stood at $18.5 million (down 10.57% YoY), and the FY2025 full-year result was $19.1 million, down 9.93% from the prior year.
• Operating Leases eased to $18.5 million in Q1 2026, from $19.1 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $24.5 million in Q2 2022 to a low of $70000.0 in Q1 2022.
• A 5-year average of $20.7 million and a median of $22.1 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases sank 96.46% in 2022 and surged 34060.0% in 2023, its largest moves.
• Tracing SLDB's Operating Leases over 5 years: stood at $24.3 million in 2022, then fell by 6.47% to $22.7 million in 2023, then slipped by 6.82% to $21.2 million in 2024, then dropped by 9.93% to $19.1 million in 2025, then slipped by 3.04% to $18.5 million in 2026.
• Business Quant data shows SLDB's Operating Leases at $18.5 million in Q1 2026, $19.1 million in Q4 2025, and $19.6 million in Q3 2025.